(https://www.cnbc.com/2026/07/29/novo-nordisk-lawsuit-cagrisema-weight-loss-drug.html) over CagriSema tolerability — but the lawsuit headlines obscure a sharper question about revenue deceleration. NVO posted in annual revenue with net margin, but the 4Q sequence tells a volatile story: → → $35.4B → $27.0B shows steep sequential compression into the year.

Research these companies